At the time of publication, 17 countries are funding pemigatinib based on the results of FIGHT 202, and numerous biliary tract guidelines recommend pemigatinib as the preferred treatment for previously treated advanced/metastatic CCA with an FGFR2 fusion or another rearrangement [7,8,20]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.